Platform Extension (e.g., Cardioneuroablation)
Cardiac Arrhythmias
Development/ExplorationActive
Key Facts
About inHEART
inHEART is a private, Bordeaux-based company founded in 2017, specializing in AI-powered cardiac imaging software. Its core platform creates a patient-specific digital twin of the heart from standard medical images, providing electrophysiologists with unprecedented anatomical insights to plan and guide ablation therapies, primarily for ventricular tachycardia. The company is in a commercial stage, with its solution integrated into over 300 partner hospitals across 40+ countries, and is backed by investors like SWEN Capital Partners. Its value proposition centers on reducing procedure times and improving success rates for complex cardiac ablations.
View full company profileTherapeutic Areas
Other Cardiac Arrhythmias Drugs
| Drug | Company | Phase |
|---|---|---|
| nsPFA Navigation (Pulse Biosciences) | CardioNXT | Pre-clinical |
| Cardiac Arrhythmia Program | Current Surgical | Research |
| MicroPort EverPace™ PulseMagic™ TrueForce® PFA Catheter | MicroPort | NMPA Approved |
| Aveir DR Dual-Chamber Leadless Pacemaker | Abbott | Clinical Investigation |